EORTC protocol 40052 - PETACC-8

Adjuvant treatment of fully resected stage III colon cancer with folfox-4 versus folfox-4 plus cetuximab (PETACC-8)
Trial StatusClosed for recruitment
DatesDate of activation: 02-Jan-06
Closed on : 05-Nov-09
Data management at EORTCNone
Phase3
Randomized trialYes
TypeAdjuvant
Targeted Sample sizeEORTC Groups: 150 - All Groups: 2000
Number of steps1
DrugFluorouracil
Cetuximab
Leucovorin
Oxaliplatin
Study StaffEric Van Cutsem (Study Coordinator) - U.Z. Leuven - Campus Gasthuisberg, Leuven
Laurence Collette (Statistician) - EORTC Headquarters, Brussels
Sandrine Marreaud (Coordinating Physician) - EORTC Headquarters, Brussels
Michel Praet (Project Manager) - EORTC Headquarters, Brussels, michel.praet( at )eortc.be, +32 27741672
Type of cancerColon
Participating GroupsFederation Francophone de Cancerologie Digestive(Coordinating Group)
EORTC Gastrointestinal Tract Cancer Group
Arbeitsgemeinschaft Internistische Onkologie
Association Europeenne de Rcherche en Oncologie
Austrian Breast and Colorectal Cancer Study Group
Belgian Group of Digestive Oncology
FNCLCC
Grupo Coop. do Cancro Dig. da Ass. Portuguesa Inv. Onco.
Grupo Espanol para el Tratamiento de Tumores Digestivos
Gruppo Italiano Studio Carcinomi Apparato Digerente
Gruppo Oncologico Chirurgico Cooperativo Italiano
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT number
EudraCT2005-003463-23
Protocol documents in PDF
(requires password)
Study documentation
Back to Protocol section